At the news
? BULLISHIMPACT 8/10 8-K filed Mar 31, 2026 at 16:54 ET
Kodiak Sciences reported Q4 2025 net loss of $56.7M ($1.04/share), missing consensus by $0.03, driven by increased R&D spend. The filing was dominated by positive clinical news: strong Phase 3 GLOW2 topline results for Zenkuda (tarcocimab) in diabetic retinopathy, showing 62.5% of patients achieved ≥2-step improvement in DRSS vs. 3.3% for sham (p<0.0001), with an 85% risk reduction in sight-threatening complications. The company announced an accelerated path toward a multi-indication BLA submission and ended the year with $209.9M in cash after a $173M equity raise.
- Positive Phase 3 GLOW2 topline results for Zenkuda in diabetic retinopathy: 62.5% of patients achieved ≥2-step improvement in DRSS vs. 3.3% for sham (p<0.0001).
- 85% risk reduction in sight-threatening complications with Zenkuda vs. sham (2.4% vs. 15.8%, p=0.0001).
- Company announced an accelerated timeline for a multi-indication Biologics License Application (BLA) submission for Zenkuda.
- Completed a $173M follow-on equity offering in December 2025, ending the year with $209.9M in cash, up from $72.0M in Q3.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access